AptaBio Therapeutics Inc
KOSDAQ:293780
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AptaBio Therapeutics Inc
KOSDAQ:293780
|
KR |
|
FHT Holdings Corp
TSE:3777
|
JP |
|
A
|
Acroud AB
STO:ACROUD
|
SE |
|
Teka Tecelagem Kuehnrich SA
BOVESPA:TEKA4
|
BR |
|
Jayaswal Neco Industries Ltd
NSE:JAYNECOIND
|
IN |
|
I
|
iSoftStone Information Technology Group Co Ltd
SZSE:301236
|
CN |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
|
N
|
Narnia (Hong Kong) Group Co Ltd
HKEX:8607
|
CN |
|
Y
|
Yoshi Innovation SA
WSE:YOS
|
PL |
|
N
|
Northbaze Group AB
STO:NBZ
|
SE |
|
Qunabox Group Ltd
HKEX:917
|
CN |
|
Cactus Inc
NYSE:WHD
|
US |
|
Burger Fuel Group Ltd
NZX:BFG
|
NZ |
|
A
|
Anton Oilfield Services Group
HKEX:3337
|
CN |
|
Allegiant Travel Co
NASDAQ:ALGT
|
US |
|
K
|
Keck Seng Investments Hong Kong Ltd
HKEX:184
|
HK |
|
Sekar Bumi Tbk PT
IDX:SKBM
|
ID |
|
A
|
AllHome Corp
XPHS:HOME
|
PH |
|
Precision Camshafts Ltd
NSE:PRECAM
|
IN |
|
U
|
U-Haul Holding Co
NYSE:UHAL.B
|
US |
|
TongHwa Corp
TWSE:1418
|
TW |
|
R
|
Ridge-i Inc
TSE:5572
|
JP |
|
Delivery Hero SE
OTC:DLVHF
|
DE |
|
Japan Cash Machine Co Ltd
TSE:6418
|
JP |
Discount Rate
Cost of Equity
Discount Rate
AptaBio Therapeutics Inc's Cost of Equity, calculated using the formula Risk-Free Rate + Beta x ERP, stands at 8.4%. The Beta, indicating the stock's volatility relative to the market, is 1.18, while the current Risk-Free Rate, based on government bond yields, is 3.47%, and the ERP, measuring the extra return over the risk-free rate required by investors, is 4.18%.
WACC
Discount Rate
AptaBio Therapeutics Inc's Weighted Average Cost of Capital (WACC) is calculated as the weighted average of its cost of equity and cost of debt, adjusted for tax. The WACC stands at 8.4%. This includes the cost of equity at 8.4%, calculated as Risk-Free Rate + Beta x ERP, and the cost of debt at 7.1%, reflecting the interest rate on AptaBio Therapeutics Inc's debt adjusted for tax benefits. The weight of debt in the capital structure is 0.03%.
What is AptaBio Therapeutics Inc's discount rate?
AptaBio Therapeutics Inc 's current Cost of Equity is 8.4%, while its WACC stands at 8.4%. The selection of the appropriate discount rate is contingent on the type of cash flows being discounted.
For Equity Valuation: When valuing equity, especially in scenarios where you are discounting cash flows to equity holders (such as Net Income, Earnings Per Share (EPS), or Free Cash Flow to Equity), the Cost of Equity should be used.
For Firm Valuation: In contrast, when valuing the entire firm and discounting cash flows available to both debt and equity holders (like Free Cash Flow to the Firm), the Weighted Average Cost of Capital (WACC) is the appropriate rate."
How is Cost of Equity for AptaBio Therapeutics Inc calculated?
The Cost of Equity represents the return a company must offer investors to compensate for the risk of investing in its stock. It's calculated using the Capital Asset Pricing Model (CAPM), which combines the risk-free rate, the stock's beta, and the equity risk premium (ERP).
This model considers the inherent risk of investing in the stock compared to a risk-free investment and the market's overall risk.
Here is how we calculate the cost of equity for AptaBio Therapeutics Inc
How is WACC for AptaBio Therapeutics Inc calculated?
WACC, or Weighted Average Cost of Capital, is a calculation that reflects the average rate of return a company is expected to pay its security holders to finance its assets. It is a critical measure in financial analysis for valuing a company’s entire operations.
The WACC formula combines the costs of equity and debt, weighted by their respective proportions in the company's capital structure.
Here is how we calculate WACC for AptaBio Therapeutics Inc
